Brussels, 12/09/2006 (Agence Europe) - Debate is continuing at European Union institutions on the proper role for human embryonic stem cell research under both the 7th Framework Programme for Research and the regulation on centralised authorisation of the marketing of innovative therapy, and EURORDIS (an organisation of 264 patients' and patients' parents' groups from 21 countries, including 19 EU Member States, representing some 30 million sufferers of rare diseases in the EU) is clearly...